06/01/23 4:30 PMNasdaq : MRTX conferencesMirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023Mirati Therapeutics, Inc. ®, a commercial stage biotechnology company, will participate at the Goldman Sachs 44 th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T./ 11:40 a.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat at the conference. Investors and the general...RHEA-AIneutral
05/30/23 4:00 PMNasdaq : MRTX clinical trialMirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual MeetingMirati Therapeutics, Inc. ®, a commercial stage biotechnology company, today announced...RHEA-AIneutral
05/24/23 4:01 PMNasdaq : MRTX clinical trialMirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®Mirati Therapeutics, Inc. ®, a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab 1 versus docetaxel in patients with second or third line...RHEA-AIpositive
05/09/23 4:01 PMNasdaq : MRTX earningsMirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesMirati Therapeutics, Inc. ®, a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales...RHEA-AIneutral
05/05/23 4:00 PMNasdaq : MRTX Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Mirati Therapeutics, Inc. ®, a clinical-stage targeted oncology company, today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the...RHEA-AIvery positive
04/27/23 4:30 PMNasdaq : MRTX conferencesMirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care ConferenceMirati Therapeutics, Inc. ®, a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T./ 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference. About Mirati Therapeutics, Inc. ®. Mirati Therapeutics, Inc. is a...RHEA-AIneutral
04/26/23 4:34 PMNasdaq : MRTX clinical trialJournal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid TumorsMirati Therapeutics, Inc. ®, a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRAS G12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma, biliary...RHEA-AIneutral
04/25/23 4:30 PMNasdaq : MRTX conferencesearningsMirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023Mirati Therapeutics, Inc., a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET/ 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results. Mirati Therapeutics, Inc.is a...RHEA-AIneutral
04/03/23 4:00 PMNasdaq : MRTX conferencesMirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage ProgramsMirati Therapeutics, Inc., a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRAS G12C inhibitor, or an...RHEA-AIneutral
03/06/23 4:30 PMNasdaq : MRTX conferencesMirati Therapeutics to Participate at the Barclays Global Healthcare ConferenceMirati Therapeutics, Inc., a commercial stage biotechnology company, will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T./ 9:00 a.m. E.T. Ben Hickey, chief commercial officer, and Alan Sandler, chief medical officer, will represent the company in a fireside chat at the conference. Investors and the general public are...RHEA-AIneutral